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Background: Children often develop allergies that may or not persist into adulthood. Although the different
allergic symptoms over time have been well documented, the underlying pattern of sensitization to various
proteins and subsequent allergy development is unexplored.
The aim was to study the sensitization pattern to allergen components over time from infancy to adulthood in a
group of infants with heredity for allergic diseases.
Methods: IgE profiles were monitored in a group of 67 children from 6 months to 18 years using a microarray chip
(ImmunoCAPW ISAC) containing 103 allergen components derived from 47 allergen sources. The chip IgE profile
was compared with clinical history, skin prick test results and diagnoses (atopic dermatitis, asthma and allergic
rhinoconjunctivitis) at each time point for each child.
Results: IgE profiles were unique for each child and showed broad agreement with the results of skin prick tests
and doctors’ diagnoses. In addition, close examination of the IgE profiles often revealed early indication of
subsequent allergies. IgE profiles also facilitated the examination of cross-reactivity contra co-sensitization, thereby
greatly enhancing the possibility for managing patients.
Conclusion: This explorative description indicates that sensitization pattern to allergen components differs over
time as well as among allergic individuals when examined with microarray technology.
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Atopic disease is one of the most common chronic disor-
ders worldwide among both children and adults. The term
“atopic march” refers to the dynamic process of manifest-
ation, persistence, and remission of different atopic pheno-
types in the first two decades of life [1,2]. Atopic dermatitis
per se does not constitute a risk for asthma, but may do so
when associated with allergic sensitization [3]. Persistent
asthma is more likely in children with early sensitization to
indoor allergens and exposure.
Objective measurement of atopic status, including
quantification of markers of sensitization, is needed to
quantify asthma risk [3,4]. Recent research has identified
some useful indicators of potential allergy manifestation.
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reproduction in any medium, provided the orallergies, early, multiple and severe sensitization to some
food- and aeroallergens, and early viral infections [3].
Quantitative measures of atopy, especially cumulative
titers of IgE to perennial inhalant allergens, provide
more robust assessments of atopy-associated risk than
simple binary classifications (such as sensitized or non-
sensitized). Consequently, developing methods that iden-
tify early sensitization to allergens will provide a critical
step in the management of allergy manifestation in chil-
dren. Today, a substantial proportion of children who
develop persistent asthma are not identified until their
disease has already consolidated, thus preventing any
potential benefits of early intervention.
Recent studies have shown that allergen microarray
chips are novel tools for high-resolution IgE profiling in
patients with atopic dermatitits [5,6], in adult multi-
sensitized patients with respiratory symptoms [7], and
leads to a more precise diagnosis of sensitization
[8-10]. The chip technology enables a simultaneoustd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Number of children sensitized to different allergens.
White bars represent children with IgE abs observed at the same
time as symptoms were reported. Black bars represent children with
IgE abs observed at least one time episode (see Methods) prior to
any symptoms to the given allergen was reported.
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using a minimal amount of serum [8,11]. Pediatric array
studies have shown that cross-reacting pollen allergens
are absent in the first years of life [12] and that multi-
sensitization towards certain furry animal components
are associated with increased bronchial inflammation in
severe asthmatic children [13].
The aim of this study was to describe explorative the




Pregnant women (n = 67) in Linköping, Sweden were
invited to participate [14]. The babies were classified
into two groups: double heredity (n = 46) and no family
history of atopic disease (n = 21). Double heredity was
defined as atopic disease either in both parents or in one
parent and one sibling.
A clinical examination was done, and a history was
obtained regarding symptoms of allergies at 3, 6, 9, and
18 months of age, [14] at 6 years of age [15] and at 18
years of age [16]. The physical examination focused on
symptoms of allergy. Venous blood was sampled, SPTs
were performed and questionnaires were used at each
occasion. In total, 64 children completed the study, out
of which 49 were venipunctured at the last checkup.
The study was approved by the regional ethics commit-
tee at Linköping University (# 03694).
Physical examination
Atopic dermatitis was defined as proposed by Hanifin
and Raijka [17] with the use of the modified criteria for
young infants [18] and according to the SCORAD index
[19]. For children under 18 years of age, asthma was
defined as three or more episodes of bronchial obstruc-
tion verified by a physician [20]. At 18 years of age,
asthma was defined according to the changes in the
spirometric results in the exercise provocation [16].
Allergic rhinoconjunctivitis was defined as rhinitis or
conjunctivitis appearing after exposure to a particular
allergen and without any infection. The diagnosis was
based on a history of relevant symptoms (itching in eyes
or nose, tearing, eye redness, runny nose, sneezing and
nasal obstruction) having occurred at least twice during
the previous two years.
The clinical diagnosis of atopic dermatitis, asthma, and
allergic rhinoconjunctivitis was made when children were
1.5, 6, and 18 years of age. The classification was based on
physical examination and questionnaires. SPTs were per-
formed with the following allergens; egg, milk, fish animal
epithelia, birch, timothy grass, mugwort, house dust mite,
Alternaria and Cladosporium described in detail elsewhere
[14-16].Circulating IgE antibodies
Sera were analyzed using the ImmunoCAP ISAC 103
microarray chip, (Thermo Fisher Scientific, Vienna). It
contains 103 allergen components derived from 47 aller-
gen sources and used by allergy specialists and im-
munologists as a complement to other established diag-
nostic tests [21,22]. The testing procedure was carried
out according to the manufacturer's instructions for use.
The IgE results were reported in ISAC Standardized
Units (ISU). The ISAC measurement range is 0.3 – 100
ISU. For each individual a descriptive analysis of data
was carried out where each ISAC IgE response was com-
pared with the patient’s clinical history, doctor’s diagno-
sis, and SPT at each time point.
Results
Overall the clinical history and the ISAC IgE responses
were in broad agreement. Of 82 triggering allergens caus-
ing symptoms as defined by doctors diagnosis, 76 (93%)
were identified by the ISAC chip. An overview of the
sensitization profile in the study group is presented in
Figure 1. For each individual, sensitization to a given aller-
gen was compared with any clinical reaction at the same
or at a later time episode. For this purpose, a sensitization
to a given allergen was only counted once per individual.
Among the younger children, 6 to 18 months old, the top
3 most prevalent sensitizing allergen was hen’s egg (14%),
followed by cow’s milk (11%), and peanut (6%). The most
common egg components were Gal d 1 and 2 (n = 9). The
most common milk allergen was Bos d 8, which usually
occurred with concomitant sensitization to several other
milk components (n = 7). The 4 subjects with IgE anti-
bodies (hereafter, abs) to peanut components all revealed
concomitant sensitization to Ara h 1, 2, and 3. Among the
older children, 6 or 18 years old, the top 3 most prevalent
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cat (22%). IgE abs to Phl p 1 to 5 were observed in 27 out
of 64 children. Bet v 1 was the most prevalent component
for birch (n = 18), and it always occurred with concomitant
sensitization to several other PR-10 allergens from nuts and
fruits. Bet v 1 was the most frequent PR-10 protein, fol-
lowed by Cor a 1.0401, Mal d 1, Pru p 1, Ara h 8, Gly m 4,
in descending order. The major cat allergen Fel d 1 was the
most common cat component (n = 14). In young children,
the most prevalent cross-reacting allergen group was serum
albumin (n = 7, 14%). However, only three of the 1.5 year
old children, and not always the same individuals as the
seven 6 – 18 year old ones, displayed IgE to serum albumin.
Conversely, PR-10 proteins were the most prevalent cross-
reacting allergens among the older children (n = 18, 28%),
while PR-10 sensitization was absent in 6 to 9 month old
children. No detectable IgE abs was found to lipid transfer
proteins or cross-reactive carbohydrate determinants
(CCD). Profilin abs were detected only in 18-year-old
subjects (n = 5). Tropomyosin abs were detected in two
children at 1.5 year of age, one of them remained sensitized
at 6 years of age, but none at 18 years age.
Overall the performance and quality of the ISAC results
were acceptable for all patients and components except
for rAsp f 1, nBos d 8 and nBos d lactoferrin, where assay
backgrounds below < 1 ISU were registered for 20-25% of
the measurements. Hence only responses ≥ 1 ISU were
taken into consideration in the data analysis.
All children revealed unique IgE sensitization “finger-
prints” over time. No child was similar to another even
though they presented similar symptomatology. Four
subgroups of patients with common features were iden-
tified based on the sensitisation pattern over time,
see below. Eleven children were excluded from this
subgroup classification due to missing time episode
samples.
Early multiple food and aeroallergen sensitized group
(Early multi)
Ten children (19%) revealed IgE ab binding to egg and
milk early in life (< 1.5 years), sometimes with parallel
sensitization to fish or storage proteins from soy, peanut,
or tree nuts. As these children aged (i.e., became >1.5
years old), sensitization to aeroallergens such as pollen,
animal dander, or mites, became prevalent, whereas milk
and egg sensitization usually declined and vanished over
time. All clinically diagnosed allergies in this group were
confirmed by the chip results. All 10 children in this
group revealed unique IgE profiles (e.g., see Additional
file 1). By resolving co-sensitization for cross-reactivity
and by identifying unexpected triggers prior to symptom
development, the ISAC chip provided valuable informa-
tion in 8 out of 10 children in the multi-sensitized
group.Late sensitized group (Late IgE)
Twenty individuals (38%) did not reveal any sensitization
to egg, milk, fish, soy, wheat or peanut early in life, but
developed IgE abs to aeroallergens (pollen, mites, cat, or
dog) later in life (at 6 years or older), with or without
cross-reacting food allergens like PR-10 proteins. All
diagnosed allergies were detected by the ISAC chip,
except for 3 patients with SPT confirmed egg allergy. All
20 children in this group revealed unique IgE profiles
(Additional file 2). Nine of 20 children showed relatively
simple IgE profiles, with only one or two species-specific
allergens (typically mono-sensitized to birch, grass, or
cat). The remaining 11 children displayed a multi-
sensitized IgE profile, involving cross-reacting allergens
(often PR-10 proteins) with concomitant sensitization to
at least 2 species-specific components. For these more
complex, multi-sensitized children the ISAC results gave
new, relevant information not easily available from SPT
or case histories.
Early food sensitized group (F)
Two children (4%) displayed a low-level response (< 2
ISU) to one of the egg components before 1.5 years of age,
without developing any sensitization to aeroallergens later
in life. The diagnosed egg allergy was confirmed by the
chip for both children. In this case, the ISAC results did
not add new, relevant information relative to traditional
diagnostic methods. This group of patient was not studied
further due to the limited number of individuals.
Non-sensitized group (No IgE)
Twenty-one children (40%) did not reveal any IgE ab
response. In this group of patients the ISAC chip missed
two children with diagnosed egg allergy and confirming
egg SPT, and one child with diagnosed cat and dog allergy
and confirming SPT. Of these 21 children, only eight were
diagnosed at least once with atopic dermatitis, asthma, or
rhinoconjunctivitis during the 18 year follow-up. The ISAC
results did not add new, relevant information relative to
traditional diagnostic methods, except for delivering a
rapid and reliable answer that the child is non-sensitized to
a broad spectrum of allergens.
Sensitization pattern versus clinical diagnosis
Children in the early multiple food and aeroallergen sensi-
tized (Early Multi) group were more likely to have atopic
dermatitis compared to those who later were sensitized
(Late A) and non-sensitized at all ages (Figure 2). Early
multi-sensitized children also developed allergic rhinocon-
junctivitis at an earlier age compared to those who were
only aeroallergen sensitized. The percentage of children
who developed asthma did not differ between these two
groups. Half of the children who were only sensitized to an
aeroallergen also had non-IgE mediated atopic dermatitis.
Figure 2 Percentage of children in the three study groups (Early
multiple food and aeroallergen sensitization, Late IgE and No IgE)
diagnosed with atopic dermatitis, asthma, and allergic rhino-
conjunctivitis at each time point. (Since a child may have up to 3
defined symptoms n can end up to a maximum of 300%).
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atopic dermatitis, asthma, or allergic rhinoconjunctivitis
(range 0-14%).
The worst possible case scenario was for a subject to ac-
cumulate three diagnoses at each of the three time inter-
vals, adding up to a maximum of nine diagnoses. The
early multi-sensitized group accumulated a mean number
of 5.3 diagnoses, the group with late sensitization a mean
of 3.8 diagnoses, and the non-IgE group a mean of 0.7
diagnoses.
Molecular spreading over time
A number of offending allergens were identified with
IgE ab responses prior to any reported clinical reactions
to that allergen (Figure 1). We registered 22 observations
with detectable IgE abs, with at least two consecutive
time episodes, following the actual time episode to a
given allergen source (Figure 3). In 19 of these 22 obser-
vations, an initial phase with an increasing number ofFigure 3 Number of children with increasing (blue, n = 19) and
non-increasing (red, n = 3) IgE eliciting components in the
initial phase of the IgE development process.sensitizing components was observed, typically with in-
creasing IgE levels.
Discussion
We describe in this explorative study that sensitization to
allergen components in allergic children increase over time.
Based on these findings, we hypothesize that sensitization
profiling provides additional information regarding early
identification, cross-reactivity, co-sensitization and unex-
pected triggers in allergic children.
The ISAC results in this study confirm that egg and milk
were the most common sensitizing allergens among young
children, while aeroallergen components from birch, grass,
and cat were the most prevalent allergens among older
children. Interestingly, serum albumin (SA) was the most
common cross-reacting allergen among young children in
our study. SA sensitization was always accompanied by
IgE abs to several milk components, indicating that the
SA sensitization in young children originates from the
bovine SA, Bos d 6, present in milk. Melioli et. al. [12]
reported PR-10 proteins to be the most prevalent cross-
reacting protein among ten to eighteen years-old Italian
children. Our results confirm that PR-10 proteins are the
most prevalent cross-reacting allergens also in children
from Sweden. In our population cross-reacting proteins
like profilin and LTPs were absent in contrast to children
from the Mediterranean area.
Two children with egg allergy and one with pet allergy
were not detected with the ISAC chip. One reason could
be that the test results are semiquantative compared to
ImmunoCAP technology. If the recent ISAC chip with
112 components had been used, these children might
have been detected as this chip has improved sensitivity.
The ISAC results showed good agreement with SPT
and subsequent doctor’s diagnoses for each patient. In
addition to confirming known allergies, the ISAC chip
added previously unknown but relevant information in 8
of 10 children with multiple food and aeroallergen
sensitization, and in 9 out of 20 children multi-
sensitized to aeroallergens. The added information usu-
ally concerned resolving cross-reactivity from co-
sensitization. This information was not easily extracted
from data based on SPT and/or clinical history. These
results are in agreement with previous studies that have
shown the ISAC chip is especially useful in resolving IgE
profiles in multi-sensitized patients, and also adds add-
itional patient management value in about 30% of
patients visiting allergy specialist clinics [23-25].
However, sensitization is not always accompanied with
relevant allergic symptoms. Therefore only a thorough
medical evaluation by a clinician can diagnose an allergy.
Interestingly, all individuals displayed unique IgE
sensitization “fingerprints”. The individual fingerprints
were also unique over time but we identified four
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et al have described that IgE antibody responses do not
reflect a single phenotype of atopy, but a rather multiple
different atopic vulnerabilities [26]. Only one of these
atopic classes (multiple early atopic vulnerability) pre-
dicts asthma. We could not confirm this with our
equivalent FA group, maybe due to limited sample size.
However, we found that our equivalent group to mul-
tiple early atopic vulnerability developed allergic rhino-
conjunctivitis early in life.
One interesting observation in this study was that we
could document an increasing number of sensitizing
components, often with concurrently increasing IgE
levels in 19 of 22 evaluated children. Interestingly, the
IgE abs were typically detected long before any clinical
reactions were reported.
A major drawback with this study was the long sam-
pling intervals, precluded monitoring the IgE production
development phase in detail. A study design using a
higher sampling frequency is needed in order to explore
the precise developmental stages of allergies relative to
IgE profiles. The strength of this study is the long
follow-up period where allergy development up to young
adulthood could be followed in all of the included
infants.
Our results demonstrate that the allergen micro-array
chip is a promising tool in allergy diagnostics, especially
for multi-sensitized children with severe asthma and ec-
zema. Based on our findings of this explorative study, we
hypothesize that each child with an IgE mediated allergic
disease develops its own unique allergic component “fin-
gerprint” over time. With the component results avail-
able at the time of the medical examinations in the
study, we speculate that the patient management would
have been different for some of the children in this co-
hort. Further, a better understanding of the underlying
causes of the symptoms would have been possible for
many of the more complex, high risk children.
Additional files
Additional file 1: Representative patient case with early multiple
food and aeroallergens.
Additional file 2: Representative patient case with late sensitization.
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